Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Authors: Marcus Maurer, Sarbjit S. Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Clive Grattan

Source: Clinical and Translational Allergy, Vol 12, Iss 11, Pp n/a-n/a (2022)

Subject Terms: biosimilar, CT‐P39, immunoglobulin E, omalizumab, pharmacokinetics, Immunologic diseases. Allergy, RC581-607

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7022

Access URL: https://doaj.org/article/2ba1233eff264591b914b95213dfe671